Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Babyzim
- Development stage
- Unknown
- Lead developer
- Carl Zeiss Meditec
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Babyzim is an over-the-counter (OTC) oral drop formulation marketed in Israel by Sam-On (Meditec) for the treatment of constipation, flatulence, and gastric indigestion in infants and children. It is a combination product containing pepsin, nicotinic acid (niacin), and sodium glycerophosphate. Pepsin acts as a digestive enzyme to aid in protein digestion, while nicotinic acid and sodium glycerophosphate support metabolic and digestive functions to relieve symptoms of gas, bloating, and constipation.
- Brand names
- BabyzimBabyzim Drops
- Other names
- pepsin + nicotinic acid + sodium glycerophosphate
02
Targets
HCAR2 (Hydroxycarboxylic acid receptor 2)
Beyond the preview
Go deeper on Babyzim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Babyzim.